Treace Medical Concepts Earnings Call Transcripts
Fiscal Year 2026
-
Expanded to a comprehensive 3D bunion solutions portfolio, driving strong surgeon adoption and mid-single-digit procedure growth in late 2025. New MIS and fixation products are broadening market reach, while high gross margins and improved profitability position the company for continued growth in 2026.
Fiscal Year 2025
-
Revenue declined 9% in Q4 2025 due to product mix, but case volumes and adjusted EBITDA improved. 2026 guidance anticipates flat to -6% revenue, with growth expected in Q4 from new product launches and continued cost reductions.
-
A broadened product portfolio now addresses all major bunion categories, driving increased surgeon adoption and procedure volume growth, though revenue is tempered by a shift to lower ASP products. Strong gross margins, reduced cash burn, and new AI-driven technologies position the company for future growth and deeper market penetration.
-
Q3 2025 revenue grew 11% year-over-year to $50.2 million, but softness in Lapiplasty volumes and macroeconomic headwinds led to a revised full-year outlook of 1–2% revenue growth. New product launches drove case volume growth, though at lower ASPs, and cost controls improved Adjusted EBITDA loss by 49% in Q3.
-
A comprehensive portfolio of new minimally invasive and instrumented bunion correction systems is being launched, targeting significant market expansion and aiming to double business by increasing penetration. Key growth drivers include innovation in core procedures, digital solutions, and expansion into adjacent foot pathologies.
-
Q2 2025 revenue grew 7% year-over-year to $47.4 million, with improved margins and reduced losses. Expanded product launches and strong surgeon engagement support confidence in accelerating growth for the remainder of 2025, with full-year revenue guidance reaffirmed at $224–$230 million.
-
Q1 2025 revenue grew 3% year-over-year to $52.6M, with improved margins and reduced losses. New bunion systems and technologies are set to drive accelerated growth in the second half, supporting reaffirmed 2025 guidance of $224–$230M and a break-even adjusted EBITDA target.
-
Strong revenue growth and expanding product lines have solidified market leadership in the U.S. bunion market, with new MIS solutions and premium technologies driving further penetration. Enhanced reimbursement, robust clinical evidence, and a capital-light model support profitability targets for 2025 and 2026.
Fiscal Year 2024
-
Q4 2024 revenue grew 10% year-over-year to $68.7M, with full-year revenue up 12% to $209.4M. New product launches and expanding surgeon base are expected to drive 2025 revenue growth of 7–10%, with break-even Adjusted EBITDA and reduced cash burn anticipated.
-
Strong Q4 demand and reduced competitive pressures are driving momentum, with new minimally invasive and personalized technologies set to expand market share in 2025. Recent reimbursement changes and a robust product pipeline support the potential for double-digit growth next year.
-
Growth in 2024 was mixed, with new product launches like Nanoplasty expected to drive stronger revenue and market share gains in 2025. Operational leverage, a broadening portfolio, and enhanced training programs are set to support EBITDA break-even and further market expansion.
-
Q3 2024 revenue grew 11% year-over-year to $45.1 million, driven by new product adoption and expanding surgeon base. Gross margin remained stable at 80.1%, and full-year revenue guidance was raised to $204–$211 million. CMS reimbursement increases and new product launches are expected to support future growth.
-
The foot and ankle market is experiencing competitive shifts and increased interest in minimally invasive procedures, with new product launches like Nanoplasty and RedPoint PSI expected to drive growth in 2025. Proposed CMS reimbursement changes could significantly boost adoption in ASCs, while a focus on utilization and cost optimization positions the company for EBITDA profitability next year.
-
Q2 2024 revenue grew 6% year-over-year to $44.5 million, driven by increased case volumes and product adoption. Full-year guidance is reaffirmed, with new MIS products set for limited Q4 launch and broader impact in 2025. Gross margin was 80.2%, and net loss widened to $21.3 million.
-
Lapiplasty has doubled its market share in bunion surgery, but competition and a shift toward minimally invasive osteotomies are changing the landscape. Two new MIS osteotomy platforms will launch by late 2024, targeting untapped market segments. Profitability remains a focus, with cost efficiencies offsetting slower revenue growth.